Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458407 | 0.92 | PDE10A (0.71) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD | |
| SCHEMBL1458141 | 0.91 | PDE10A (0.69) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD | |
| SCHEMBL12825965 | 0.90 | PDE10A (0.76) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD | |
| SCHEMBL1457802 | 0.89 | PDE10A (0.73) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD | |
| SCHEMBL6889025 | 0.88 | PDE10A (0.81) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD | |
| SCHEMBL6889411 | 0.87 | PDE10A (0.80) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD | |
| SCHEMBL1458526 | 0.87 | PDE10A (0.82) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD | |
| SCHEMBL1457776 | 0.87 | PDE10A (0.71) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD | |
| SCHEMBL1458378 | 0.87 | PDE10A (0.71) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD | |
| SCHEMBL1458278 | 0.87 | PDE10A (0.71) | PDE10ASMN1; SMN2ALDH1A1MAPK1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480546-B1 | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | claimed |
| EP-2480546-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | claimed |
| US-8017604-B2 | Imidazopyridines | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | claimed |
| WO-2011036127-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | claimed |
| US-20110071128-A1 | NOVEL IMIDAZOPYRIDINES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | claimed |
| EP-2480546-B1 | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8263584-B2 | Imidazopyridines | HOFFMANN-LA ROCHE INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2480546-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8017604-B2 | Imidazopyridines | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| WO-2011036127-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071128-A1 | NOVEL IMIDAZOPYRIDINES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071128-A1 | NOVEL IMIDAZOPYRIDINES | PDE10A, PDE4A, PDE3A | PDE10A 1/4885SMN1; SMN2 1194/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.